Skip to main content

Table 2 First-line treatment regimens

From: Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study

 

Cohort 1

Cohort 2

Patients who received treatments

169 (100.0)

66 (100.0)

 CAM + EB + RFP

134 (79.3)

39 (59.1)

 CAM + RFP

30 (17.8)

6 (9.1)

 CAM + EB + RFP + SM

2 (1.2)

2 (3.0)

 CAM + EB

1 (0.6)

6 (9.1)

 CAM + RFP + NQ

1 (0.6)

5 (7.6)

 CAM + EB + NQ

0 (0.0)

2 (3.0)

 CAM + EB + RFP + NQ

0 (0.0)

2 (3.0)

 Other regimens

1(0.6)

4 (6.1)

  1. Data are n (%)
  2. CAM clarithromycin, RFP rifampicin, EB ethambutol, SM streptomycin, NQ new quinolones